SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 203 filers reported holding SAGE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,622,430 | -57.7% | 176,017 | -3.3% | 0.07% | -54.7% |
| Q2 2023 | $8,557,076 | +9.1% | 181,988 | -2.7% | 0.15% | -7.5% |
| Q1 2023 | $7,845,891 | +19.8% | 186,985 | +8.9% | 0.16% | +11.9% |
| Q4 2022 | $6,551,727 | -0.9% | 171,781 | +1.8% | 0.14% | -5.9% |
| Q3 2022 | $6,609,000 | +17.3% | 168,766 | -3.2% | 0.15% | +23.6% |
| Q2 2022 | $5,633,000 | -3.8% | 174,398 | -1.4% | 0.12% | +18.3% |
| Q1 2022 | $5,857,000 | -23.0% | 176,949 | -1.1% | 0.10% | -20.6% |
| Q4 2021 | $7,610,000 | -3.6% | 178,892 | +0.4% | 0.13% | -10.3% |
| Q3 2021 | $7,898,000 | +78.3% | 178,241 | +128.6% | 0.15% | +82.5% |
| Q2 2021 | $4,430,000 | -23.1% | 77,973 | +1.3% | 0.08% | -27.3% |
| Q1 2021 | $5,764,000 | -21.3% | 77,005 | -9.1% | 0.11% | -26.2% |
| Q4 2020 | $7,326,000 | +32.7% | 84,685 | -6.2% | 0.15% | +13.7% |
| Q3 2020 | $5,520,000 | +41.1% | 90,320 | -4.0% | 0.13% | +36.5% |
| Q2 2020 | $3,911,000 | – | 94,060 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
| Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
| Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
| ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
| DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
| Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
| Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
| Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
| Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
| Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |